MedTrace Logo

Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

NCT00041756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 395

Last updated 2011-11-08

Study results available
· View outcomes & findings →

Summary

Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

PG-530742

One 25 mg PG-530742 tablet, twice daily for for one year

DRUG

Placebo

One placebo tablet, twice daily for for one year

DRUG

50 mg PG-530742

One 50 mg PG-530742 tablet, twice daily for for one year

DRUG

100 mg PG-530742

100 mg PG-530742 tablet, twice a day for one year

DRUG

200 mg PG-530742

200 mg PG-530742 tablet, twice a day for one year

Sponsors & Collaborators

  • Procter and Gamble

    lead INDUSTRY

Principal Investigators

  • John Beary, MD · Procter and Gamble

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2004-02-29
Completion
2004-02-29

Countries

  • Hungary
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00041756 on ClinicalTrials.gov